Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual

Answer questions and earn CME/CNE

[1]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[2]  I. Ellis,et al.  Method for grading breast cancer. , 1993, Journal of clinical pathology.

[3]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Compton,et al.  AJCC Cancer Staging Manual , 2002, Springer New York.

[5]  I. Ellis,et al.  Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. , 2002, Histopathology.

[6]  J. Olson,et al.  Improved staging in node-positive breast cancer patients using lymph node ratio: results in 1,788 patients with long-term follow-up. , 2010, Journal of the American College of Surgeons.

[7]  Tumor size and survival in multicentric and multifocal breast cancer. , 2011, Breast.

[8]  S. Ahn,et al.  Lymph node ratio and pN staging in patients with node-positive breast cancer: a report from the Korean breast cancer society , 2011, Breast Cancer Research and Treatment.

[9]  N. Duraker,et al.  The Prognosis of Tumors with only Microscopic Skin Involvement without Clinical T4b Signs is Significantly Better than T4b Tumors in Breast Carcinoma , 2011, The breast journal.

[10]  M. M. M. Anees B. Chagpar MD,et al.  Lymph Node Ratio Should Be Considered for Incorporation into Staging for Breast Cancer , 2011, Annals of Surgical Oncology.

[11]  G. Hortobagyi,et al.  Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  N. Duraker,et al.  Lymph Node Ratio May Be Supplementary to TNM Nodal Classification in Node-positive Breast Carcinoma Based on the Results of 2,151 Patients , 2013, World Journal of Surgery.

[13]  J. Wesseling,et al.  A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study , 2013, International journal of cancer.

[14]  A. Giuliano,et al.  Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. , 2014, JAMA surgery.

[15]  W. V. van Harten,et al.  Optimized outcome prediction in breast cancer by combining the 70-gene signature with clinical risk prediction algorithms , 2014, Breast Cancer Research and Treatment.

[16]  1963 First prospective outcome data in 930 patients with more than 5 year median follow up in whom treatment decisions in clinical practice have been made incorporating the 21-Gene Recurrence Score , 2015 .

[17]  John M S Bartlett,et al.  An international study to increase concordance in Ki67 scoring , 2015, Modern Pathology.

[18]  Virginia G Kaklamani,et al.  Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. , 2015, The New England journal of medicine.

[19]  Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98% , 2016 .

[20]  L. V. van't Veer,et al.  70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer. , 2016, The New England journal of medicine.

[21]  S. Shak,et al.  West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Bast,et al.  Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Abstract P5-15-01: Breast cancer specific survival in 38,568 patients with node negative hormone receptor positive invasive breast cancer and oncotype DX recurrence score results in the SEER database , 2016 .

[24]  Breast cancer specific survival in patients with node-positive hormone receptor positive invasive breast cancer and Oncotype DX recurrence score results in the SEER database. , 2016 .

[25]  C. Compton,et al.  The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer staging , 2017, CA: a cancer journal for clinicians.